Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices

INTERNATIONAL ISOTOPES INC. ANNOUNCES THE ACQUISITION OF THE AMICI INC. PRODUCT LINE

Retrieved on: 
Wednesday, June 21, 2023

IDAHO FALLS, Idaho, June 21, 2023 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) ("International Isotopes," "INIS" or the "Company") is pleased to announce that it has acquired the manufacturing molds, device registrations, trademarks, and all production rights to the AMICI Inc. line of nuclear lung ventilation products. AMICI Inc. had been a leading manufacturer and distributor of diagnostic and therapeutic products for Lung Ventilation, including masks, mouthpieces, bacteria/virus filters, absorbents, and the revolutionary Swirler® Radioaerosol System. This acquisition will further compliment the Company's RadQual business line of nuclear medicine related product offerings.

Key Points: 
  • AMICI Inc. had been a leading manufacturer and distributor of diagnostic and therapeutic products for Lung Ventilation, including masks, mouthpieces, bacteria/virus filters, absorbents, and the revolutionary Swirler® Radioaerosol System.
  • This acquisition will further compliment the Company's RadQual business line of nuclear medicine related product offerings.
  • Shahe Bagerdjian, President of INIS commented, "We're excited to be able to revive such a well established and trusted line of medical devices and I'd like to thank AMICI and Michael Bono, President of AMICI, for entrusting INIS to carry on his legacy and continue to serve the Nuclear Medicine community.
  • There's a lot of overlap in distributors and customers for both our RadQual product line and the Swirler® and Tru-Fit™ products; and we're looking forward to a smooth integration."

BlackBerry Delivers More Security, Less Complexity with Enhanced Cybersecurity Solutions Portfolio

Retrieved on: 
Monday, April 24, 2023

SAN FRANCISCO, April 24, 2023 /PRNewswire/ -- BlackBerry Limited (NYSE: BB; TSX: BB) today announced a revamped AI-based Cylance® cybersecurity portfolio that advances the company's mission to deliver enterprise-grade security assurances to organizations at a fraction of the time, effort, and initial capital typically required.

Key Points: 
  • Having the right cybersecurity solutions in place at the right time is critical," said Nathan Jenniges, Vice President of Cybersecurity Product Management at BlackBerry.
  • (Includes CylancePROTECT®, CylanceOPTICS®, CylancePROTECT® Mobile MTD)
    CylanceGUARD® now includes secure Critical Event Management (CEM) capabilities powered by BlackBerry® AtHoc®.
  • "Time-strapped security teams need solutions that bring people, processes, and technology together into consolidated solutions that can proactively hunt down and eradicate threats wherever they appear."
  • For more information on how BlackBerry's comprehensive AI-driven cybersecurity solutions can help your business prepare for, prevent, detect, and respond to cyber threats, visit BlackBerry.com .

New Play and Patio Collections from Backyard Discovery will Take any Backyard from Drab to Fab this Spring

Retrieved on: 
Thursday, April 13, 2023

In addition to adding beauty and function, Backyard Discovery products are all built to withstand the outdoor elements including sun, rain, extreme temperatures, and high winds.

Key Points: 
  • In addition to adding beauty and function, Backyard Discovery products are all built to withstand the outdoor elements including sun, rain, extreme temperatures, and high winds.
  • “Backyard Discovery has been a trusted resource for homeowners for over 30 years.
  • We pride ourselves on creating durable, premium products that are also affordable,” said Heather Napier, Director of Marketing for Backyard Discovery.
  • For more information on Backyard Discovery, or their new line of products, please visit www.backyarddiscovery.ca or follow them on Facebook , Instagram and Pinterest.

The New Play and Patio Collections from Backyard Discovery will Take any Backyard from Drab to Fab this Spring

Retrieved on: 
Thursday, April 13, 2023

In addition to adding beauty and function, Backyard Discovery products are all built to withstand the outdoor elements including sun, rain, extreme temperatures, and high winds.

Key Points: 
  • In addition to adding beauty and function, Backyard Discovery products are all built to withstand the outdoor elements including sun, rain, extreme temperatures, and high winds.
  • “Backyard Discovery has been a trusted resource for homeowners for over 30 years.
  • We pride ourselves on creating durable, premium products that are also affordable,” said Heather Napier, Director of Marketing for Backyard Discovery.
  • For more information on Backyard Discovery, or their new line of products, please visit www.backyarddiscovery.com or follow them on Facebook , Instagram and Pinterest.

PaxMedica Holds Meeting of Scientific Advisory Board

Retrieved on: 
Monday, March 20, 2023

TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it held a Scientific Advisory Board meeting on March 10-12, 2023.  A number of new members have been added to the board, which consists of many key opinion leaders in autism spectrum disorder (ASD) in the United States including:

Key Points: 
  • Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S.
    TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it held a Scientific Advisory Board meeting on March 10-12, 2023.
  • We continue to be very excited about studying a product for the potential treatment of the core symptoms of autism spectrum disorder.”
    Dr. Robert Naviaux added, “At the scientific advisory board meeting this weekend, experts from many different areas of medicine came together to share their thoughts on how suramin may work in ASD and how it might work in several other complex disorders.
  • What emerged was a clear vision for the next steps needed to test suramin in autism.
  • This is expected to be done in a series of international, multicenter, clinical trials that are projected to begin in 2024.”

External Validation Confirms Included Health Navigation Offering Can Lower Healthcare Cost Trend by 6-10 Percentage Points for Employers

Retrieved on: 
Wednesday, November 30, 2022

Included Health , the first company to fully integrate navigation and virtual care, today released its Premium Navigation Trend Validation Summary Report.

Key Points: 
  • Included Health , the first company to fully integrate navigation and virtual care, today released its Premium Navigation Trend Validation Summary Report.
  • The report details the external validation of its Premium Navigation offering by Avalere Health and Validation Institute, along with a deeper analysis to understand what contributed to the trend results.
  • One key takeaway from the report is Avaleres validation of Included Healths methodology concluding that Premium Navigation can deliver a 610 percentage point lower healthcare cost trend than a comparable national benchmark.
  • To learn more about how Included Healths validated offerings can help reduce healthcare trend via meaningful clinical engagement, download the Premium Navigation Trend Validation Summary Report .

SureWerx® Acquires Oberon Company

Retrieved on: 
Thursday, November 3, 2022

SureWerx, a leading global provider of safety, tool & equipment products, announced today that it has acquired Oberon Company.

Key Points: 
  • SureWerx, a leading global provider of safety, tool & equipment products, announced today that it has acquired Oberon Company.
  • Adding Oberon to our growing, world-class portfolio of SureWerx brands moves us further toward our goal of becoming the global leader in Safety and Productivity, said SureWerx CEO Chris Baby.
  • We are thrilled to be partnering with SureWerx, a company that holds the same values and commitment to worker safety as Oberon.
  • SureWerx markets its safety products under multiple brands including Jackson Safety, Sellstrom, Pioneer, PeakWorks, ADA Solutions, Due North, K1 Series, Avenger, Nautilus, MEGAComfort, NEOS, and now Oberon.

SureWerx™ Acquires NEOS Overshoe® Brand

Retrieved on: 
Tuesday, October 4, 2022

SureWerx, a leading global manufacturer of safety, tool & equipment products, announced today that it has acquired NEOS Overshoe from Rocky Brands Inc. (NASDAQ: RCKY).

Key Points: 
  • SureWerx, a leading global manufacturer of safety, tool & equipment products, announced today that it has acquired NEOS Overshoe from Rocky Brands Inc. (NASDAQ: RCKY).
  • View the full release here: https://www.businesswire.com/news/home/20221003005048/en/
    Since 1993, NEOS Overshoe has been designing and manufacturing premium overshoes built to protect workers and consumers alike from the elements.
  • SureWerx CEO, Chris Baby, shared that Adding NEOS Overshoe to our ever growing, world-class portfolio of SureWerx brands moves us another step toward our goal of becoming the global leader in Safety and Productivity.
  • As with the recent MEGAComfort acquisition, we see tremendous opportunities to leverage the NEOS Overshoe brand across our broad spectrum of distributors and end users alike.

SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program

Retrieved on: 
Monday, March 7, 2022

STEMTRA is a randomized, double-blind, surgical sham-controlled trial evaluating the efficacy and safety of SB623 in patients with chronic motor deficits secondary to traumatic brain injury.

Key Points: 
  • STEMTRA is a randomized, double-blind, surgical sham-controlled trial evaluating the efficacy and safety of SB623 in patients with chronic motor deficits secondary to traumatic brain injury.
  • In this study, SB623 met its primary endpoint, with patients treated with SB623 achieving statistically significant improvement in motor function compared with sham surgery.
  • The Japan SB623 chronic TBI program received designation for priority review from MHLW under the Sakigake Designation System, and the Company Group filed for approval within this framework, based on the comprehensive Sakigake evaluation consultations held through January 31, 2022.
  • The Company is pursuing manufacture and marketing approval for SB623 to offer a new treatment option as soon as possible to patients suffering from chronic impairment of TBI, an area of high unmet medical need.